Komori
Business alliance4263SUSMED,Inc.Information and Communications, Services and Others

Notice concerning the execution of an agreement with Shionogi & Co.,Ltd. to finalize the milestone payment amount and terminate the exclusive distribution agreement

The exclusive sales agreement with Shionogi & Co., Ltd. for the insomnia app was terminated by mutual agreement. The milestone payment for inclusion in the national health insurance reimbursement system has been finalized at ¥200 million and is expected to be recognized as business revenue in the first quarter of the fiscal year ending June 2027.

Worth reading
62In focus
Scored from 4 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
200000000
¥
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Discontinuation
4263SUSMED,Inc.
Alliance partnerShionogi & Co.,Ltd.
Details of the alliance
  1. 1

    Milestone payment finalized at ¥200 million

  2. 2

    Execution of an agreement on termination of the contract

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

Numerical targets under the alliance

Number of medical institutions adopting the app: 1000, Number of prescriptions: 2000 per month

About the partner
LocationKita Ward, Osaka City
Impact on Business Performance

The impact on the Company's results for the fiscal year ending June 2027 from executing the agreement on termination of the contract is expected to be minor. The ¥200 million milestone payment is expected to be recognized as business revenue in the first quarter of the fiscal year ending June 2027.

Contract Date26 August 2026
Agreements reached under this partnership
ItemDetails
Name of alliance partnerShionogi & Co.,Ltd.
Alliance partner's locationKita Ward, Osaka City
Type of allianceDiscontinuation
Details of the allianceMilestone payment finalized at ¥200 million, Execution of an agreement on termination of the contract
Numerical targets under the allianceNumber of medical institutions adopting the app: 1000, Number of prescriptions: 2000 per month
Contract Date26 August 2026
Impact on Business PerformanceThe impact on the Company's results for the fiscal year ending June 2027 from executing the agreement on termination of the contract is expected to be minor. The ¥200 million milestone payment is expected to be recognized as business revenue in the first quarter of the fiscal year ending June 2027.
Items this document does not state (16)
Alliance partner's business activitiesAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Following repeated discussions between the two companies regarding the future handling of the agreement, they agreed to terminate it. The Company states that the termination was not due to any issue with the app itself or a unilateral cancellation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice concerning the execution of an agreement with Shionogi & Co.,Ltd. to finalize the milestone payment amount and terminate the exclusive distribution agreement | SUSMED,Inc. (4263) timely disclosure | Komori